app stores. Game developers relied on Tapjoy to generate revenue for themselves and offer gamers a way to earn currency to enhance their play. However, Tapjoy's failure to screen fraudulent offers left both gamers and developers holding the bag.

The settlement proposed today should help reverse the lax policing practices that led hundreds of thousands of gamers to file complaints. But when it comes to addressing the deeper structural problems in this marketplace that threaten both gamers and developers, the Commission will need to use all of its tools—competition, consumer protection, and data protection—to combat middlemen mischief, including by the largest gaming gatekeepers.

[FR Doc. 2021–00568 Filed 1–12–21; 8:45 am]

**BILLING CODE 6750–01–P**

## DEPARTMENT OF DEFENSE

## GENERAL SERVICES ADMINISTRATION

## NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

**[OMB Control No. 9000–0200; Docket No. 2020–0053; Sequence No. 19]**

### Submission for OMB Review; Protecting Life in Global Health Assistance

**Correction**

In notice document 2020–28152 appearing on pages 83086–83087 in the issue of Monday, December 21, 2020, make the following correction:

On page 83087, in the first column, in the **DATES** section, change ''January 20, 2021'' to read ''January 21, 2021.''

[FR Doc. C1–2020–28152 Filed 1–12–21; 8:45 am]

**BILLING CODE 1301–00–D**

## GENERAL SERVICES ADMINISTRATION

**[Notice-MG–2021–01; Docket No. 2021–0002; Sequence No. 1]**

### Office of Federal High-Performance Buildings; Green Building Advisory Committee; Notification of Upcoming Web Meeting

**AGENCY:** Office of Government-Wide Policy, General Services Administration (GSA).

**ACTION:** Meeting notice.

**SUMMARY:** In accordance with the requirements of the Federal Advisory Committee Act, this notice provides the agenda for the January 28, 2021 Web meeting of the Green Building Advisory Committee (the Committee). Interested individuals must register to attend as instructed below under Supplementary Information.

**DATES:** The Committee's Web meeting will be held on Thursday, January 28, 2021, from 11:00 a.m. to 4:30 p.m. Eastern time (ET).

**FOR FURTHER INFORMATION CONTACT:** Dr. Ken Sandler, Designated Federal Officer, Office of Federal High-Performance Buildings, Office of Government-wide Policy, General Services Administration, 1800 F Street NW, (Mail-code: MG), Washington, DC 20405, at *ken.sandler@gsa.gov* or 202–219–1121. Additional information about the Committee, including meeting materials and agendas, will be available on-line at *http://www.gsa.gov/gbac.*

**SUPPLEMENTARY INFORMATION:**

**Procedures for Attendance and Public Comment**

Contact Dr. Ken Sandler at *ken.sandler@gsa.gov* or 202–219–1121 to register to attend the Committee meeting. To attend, submit your full name, organization, email address, and phone number. Requests to attend the meeting must be received by 5:00 p.m. ET, on Monday, January 25, 2021. (GSA will be unable to provide technical assistance to any listener experiencing technical difficulties. Testing access to the Web meeting site before the calls is recommended.)

Contact Dr. Sandler to register to comment during the meeting public comment period. Registered speakers/organizations will be allowed a maximum of five minutes each and will need to provide written copies of their presentations. Requests to comment at the meeting must be received by 5:00 p.m., ET, on Monday, January 25, 2021.

**Background**

The Administrator of GSA established the Committee on June 20, 2011 (**Federal Register**/Vol. 76, No. 118) pursuant to Section 494 of the Energy Independence and Security Act of 2007 (EISA, 42 U.S.C. 17123). Under this authority, the Committee provides independent policy advice and recommendations to GSA to advance federal building innovations in planning, design, and operations to reduce costs, enable agency missions, enhance human health and performance, and minimize environmental impacts.

**January 28, 2021 Meeting Agenda**

- Updates and introductions
- Embodied energy task group findings & recommendations
- Election for Committee Chair
- Sustainable response to COVID–19 task group findings & recommendations
- Energy storage task group findings & recommendations
- New committee directions & topics to explore
- Public comment
- Next steps and closing comments

**Kevin Kampschroer,**

*Federal Director, Office of Federal High-Performance Buildings, General Services Administration.*

[FR Doc. 2021–00515 Filed 1–12–21; 8:45 am]

**BILLING CODE 6820–14–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2008–N–0312]**

### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Extralabel Drug Use in Animals

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Submit written comments (including recommendations) on the collection of information by February 12, 2021.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under Review—Open for Public Comments'' or by using the search function. The OMB control number for this information collection is 0910–0325. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, *PRAStaff@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

**Extralabel Drug Use for Animals—21 CFR 530**

*OMB Control Number 0910–0325—Extension*

The Animal Medicinal Drug Use Clarification Act of 1994 (Pub. L. 103–396) allows a veterinarian to prescribe the extralabel use of approved new animal drugs. Also, it permits FDA, if it finds that there is a reasonable probability that the extralabel use of an animal drug may prevent the risk to the public health, to establish a safe level for a residue from the extralabel use of the drug and to require the development of an analytical method for the detection of residues above that established safe level (21 CFR 530.22(b)). Although to date, we have not established a safe level for a residue from the extralabel use of any new animal drug and, therefore, have not required the development of analytical methodology, we believe that there may be instances when analytical methodology will be required. We are, therefore, estimating the reporting burden based on two methods being required annually. The requirement to establish an analytical method may be fulfilled by any interested person. We believe that the sponsor of the drug will be willing to develop the method in most cases. Alternatively, FDA, the sponsor, and perhaps a third party may cooperatively arrange for method development. The respondents may be sponsors of new animal drugs; State, Federal, and/or State Agencies; academia; or individuals.

In the **Federal Register** of August 6, 2020 (85 FR 47794), we published a 60-day notice requesting public comment on the proposed collection of information. One comment was received but was not responsive to topics solicited regarding the information collection.

We estimate the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN [1]

| 21 CFR part | Number of respondents | Number of responses per respondent | Total annual responses | Average burden per response | Total hours |
|---|---|---|---|---|---|
| 530.22(b); Submission(s) of Analytical Method ..... | 2 | 1 | 2 | 4,160 | 8,320 |

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.

Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

Dated: January 5, 2021.

**Lauren K. Roth,**

*Acting Principal Associate Commissioner for Policy.*

[FR Doc. 2021–00475 Filed 1–12–21; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2010–N–0161]**

### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Export of Food and Drug Administration-Regulated Products: Export Certificates

**Correction**

In notice document 2020–28064 appearing on pages 83091–83092 in the issue of Monday, December 21, 2020, make the following correction:

On page 83091, in the second column, in the **DATES** section, change ''January 20, 2021'' to read ''January 21, 2021.''

[FR Doc. C1–2020–28064 Filed 1–12–21; 8:45 am]

**BILLING CODE 1301–00–D**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2014–N–0913]**

### Agency Information Collection Activities; Proposed Collection; Comment Request; 513(g) Request for Information

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection burden estimate for requests for a written statement from FDA regarding the classification and regulatory requirements that may be applicable to a particular device (513(g) requests).

**DATES:** Submit either electronic or written comments on the collection of information by March 15, 2021.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before March 15, 2021. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of March 15, 2021. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

**Electronic Submissions**

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your